C9070 Tafasitamab-cxix - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Tafasitamab-cxix

Brand Name:

Monjuvi

Strength:

2mg

HCPCS:

C9070

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

CD19

Oral (Y/N):

FDA Approval Year:

2020

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2021

CMS Discontinuation Date:

April 1, 2021

Status:

No Longer Used